|  |  |  |  |
| --- | --- | --- | --- |
|  | OVERALL | PLAQUE BRACHYTHERAPY | GKSRS |
| SAMPLE SIZE: | **N = 245** | **N = 118** | **N = 127** |
| AGE: *Years, Avg (Min-Max)* | 63.3 (14.9 - 98.1) | 62.7 (14.9 – 87.9) | 63.8 (25.5 – 98.1) |
| RACE: | | | |
| White | 242 (99%) | 116 (98%) | 126 (99%) |
| African American | 1 (<1%) | 0 | 1 (1%) |
| Hispanic/Latino | 2 (<1%) | 2 (2%) | 0 |
| SEX: | | | |
| Male | 129 (53%) | 60 (51%) | 69 (54%) |
| Female | 116 (47%) | 58 (49%) | 58 (46%) |
| EYE: | | | |
| Left (OS) | 126 (51%) | 65 (55%) | 61 (48%) |
| Right (OD) | 119 (49%) | 53 (45%) | 66 (52%) |
| INITIAL BCVA: *Avg (Range)* | 0.4 (-0.1 – 2.8) | 0.34 (0 – 2.4) | 0.44 (-0.1 – 2.8) |
| TUMOR CHARACTERISTICS: | | | |
| Location: | | | |
| Choroidal | 222 (91%) | 105 (89%) | 117 (92%) |
| Ciliary Body | 2 (1%) | 1 (1%) | 1 (1%) |
| Cilio-Choroidal | 17 (7%) | 9 (8%) | 8 (6%) |
| Conjunctival | 1 (<1%) | 1 (1%) | 0 |
| Irido-Ciliary | 2 (1%) | 1 (1%) | 1 (1%) |
| Iris | 1 (<1%) | 1 (1%) | 0 |
| Optic Nerve Abutment: | | | |
| No | 182 (74%) | 103 (87%) | 79 (62%) |
| Yes | 62 (25%) | 14 (12%) | 48 (38%) |
| N/A | 1 (<1%) | 1 (1%) | 0 |
| ­­Tumor Height: *Avg (Range)* | 5.3 (1 – 15.65) | 4.6 (1 – 9.9) | 5.98 (1.93 – 15.65) |
| Tumor Diameter: *Avg (Range)* | 11.7 (2 – 27) | 11.2 (2 – 22) | 12 (2 – 27) |
| Internal Reflectivity: | | | |
| Very Low | 1 (<1%) | 1 (1%) | 0 |
| Low | 28 (11%) | 9 (8%) | 19 (15%) |
| Low-Medium | 32 (13%) | 12 (10%) | 20 (16%) |
| Medium | 50 (20%) | 19 (16%) | 31 (24%) |
| Medium-High | 5 (2%) | 3 (3%) | 2 (2%) |
| High | 6 (2%) | 3 (3%) | 3 (2%) |
| Unknown | 120 (49%) | 69 (58%) | 51 (40%) |
| N/A | 3 (1%) | 2 (2%) | 1 (1%) |
| Subretinal Fluid (SRF): | | | |
| Yes | 177 (72%) | 79 (67%) | 98 (77%) |
| No | 68 (28%) | 39 (33%) | 29 (23%) |
| Orange Pigment: | | | |
| Yes | 70 (29%) | 34 (29%) | 36 (28%) |
| No | 175 (71%) | 84 (71%) | 91 (72%) |
| STAGE AT DIAGNOSIS: | | | |
| Overall Stage: | | | |
| Stage 1 | 88 (36%) | 43 (36%) | 45 (35%) |
| Stage 2A | 74 (30%) | 50 (42%) | 24 (19%) |
| Stage 2B | 47 (19%) | 13 (11%) | 34 (27%) |
| Stage 3A | 27 (11%) | 8 (7%) | 19 (15%) |
| Stage 3B | 6 (2%) | 2 (2%) | 4 (3%) |
| Stage 3C | 1 (<1%) | 1 (1%) | 0 |
| Stage 4 | 2 (1%) | 1 (1%) | 1 (1%) |
| T-Stage: | | | |
| T1a | 88 (36%) | 43 (36%) | 45 (35%) |
| T1b | 2 (1%) | 2 (2%) | 0 |
| T1c | 0 | 0 | 0 |
| T1d | 0 | 0 | 0 |
| T2a | 72 (29%) | 48 (41%) | 24 (19%) |
| T2b | 2 (1%) | 0 | 2 (2%) |
| T2c | 0 | 0 | 0 |
| T2d | 0 | 0 | 0 |
| T3a | 46 (19%) | 14 (12%) | 32 (25%) |
| T3b | 9 (4%) | 5 (4%) | 4 (3%) |
| T3c | 1 (<1%) | 0 | 1 (1%) |
| T3d | 2 (1%) | 2 (2%) | 0 |
| T4a | 17 (7%) | 3 (3%) | 14 (11%) |
| T4b | 5 (2%) | 0 | 5 (4%) |
| T4c | 0 | 0 | 0 |
| T4d | 1 (<1%) | 1 (1%) | 0 |
| T4e | 0 | 0 | 0 |
| N-Stage: | | | |
| N0 | 155 (63%) | 68 (58%) | 87 (69%) |
| N1 | 0 | 0 | 0 |
| Nx | 90 (37%) | 50 (42%) | 40 (31%) |
| M-Stage: | | | |
| M0 | 183 (75%) | 79 (67%) | 104 (82%) |
| M1a | 1 (<1%) | 0 | 1 (1%) |
| M1b | 1 (<1%) | 1 (1%) | 0 |
| M1c | 0 | 0 | 0 |
| Mx | 60 (24%) | 38 (32%) | 22 (17%) |
| INITIAL STAGING SCAN: | | | |
| Yes | 183 (75%) | 79 (67%) | 104 (82%) |
| No | 55 (22%) | 36 (31%) | 19 (15%) |
| Inappropriate Scan | 7 (3%) | 3 (3%) | 4 (3%) |
| SYMPTOMS: | | | |
| Yes | 174 (71%) | 89 (75%) | 85 (67%) |
| No | 71 (29%) | 29 (25%) | 42 (33%) |
| Vision Loss / Blurred Vision: | | | |
| Yes | 110 (45%) | 56 (47%) | 54 (43%) |
| No | 135 (55%) | 62 (53%) | 73 (57%) |
| Visual Field Defect: | | | |
| Yes | 26 (11%) | 10 (8%) | 16 (13%) |
| No | 219 (89%) | 108 (92%) | 111 (87%) |
| Flashes / Photopsia: | | | |
| Yes | 66 (27%) | 44 (37%) | 22 (17%) |
| No | 179 (73%) | 74 (63%) | 105 (83%) |
| Floaters: | | | |
| Yes | 55 (22%) | 35 (30%) | 20 (16%) |
| No | 190 (78%) | 83 (70%) | 107 (84%) |
| Pain: | | | |
| Yes | 12 (5%) | 8 (7%) | 4 (3%) |
| No | 233 (95%) | 110 (3%) | 123 (97%) |